Vasomedical WKN 882846 Rebounder?!
Seite 6 von 7 Neuester Beitrag: 25.04.21 01:58 | ||||
| Eröffnet am: | 07.12.12 14:37 | von: Bergkämpfer | Anzahl Beiträge: | 152 |
| Neuester Beitrag: | 25.04.21 01:58 | von: Karolintszta | Leser gesamt: | 36.901 |
| Forum: | Hot-Stocks | Leser heute: | 6 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 1 | 2 | 3 | 4 | 5 | | 7 > | ||||
sie teilen sich den markt mit einem konkurrenten und erlauben ihm den Vertrieb in China.http://www.ariva.de/news/...national-Marketing-of-ECP-Systems-4999750
WESTBURY, N.Y., April 16, 2014
WESTBURY, N.Y., April 16, 2014 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices, including EECP® Therapy systems, the gold standard of ECP therapy, today announced that it has entered into an agreement with Chongqing PSK-Health Sci-Tech Development Co., Ltd. ("PSK") of Chongqing, China, a leading manufacturer of ECP therapy systems in China, to form a joint venture company, VSK Medical Limited ("VSK"), for the global marketing and sale of EECP and ECP therapy systems.
The agreement provides for Vasomedical and PSK to appoint the joint venture company as the exclusive distributor to market, distribute and sell EECP and ECP therapy products globally, except for the United States and China. In this regard, the agreement provides for PSK to be the exclusive distributor of Vasomedical's EECP therapy systems in China and for Vasomedical to be the exclusive distributor of PSK's ECP therapy systems in the United States, subject to certain conditions.
"Chongqing PSK in the last several years has been actively revitalizing the Chinese market for external counterpulsation treatment and has become a serious competitor in the international market," stated Dr. Jun Ma, President and CEO of Vasomedical, Inc. "This cooperative venture with PSK will enable the partners to better serve the global external counterpulsation market by offering tiered products to meet various demands for the therapy. It should also allow us to substantially reduce the risks and expenses associated with our international plan for EECP therapy.
"Our global strategy is designed to bring the combined resources of both companies to the marketing and clinical development of external counterpulsation therapy. The ultimate goal is to broaden the reach of this powerful technology so that more patients worldwide may enjoy its benefits," concluded Dr. Ma.
About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: Vasomedical Solutions, Vasomedical Global and VasoHealthcare. Vasomedical Solutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain markets. Additional information is available on the Company's website at www.vasomedical.com
About Chongqing PSK-Health
Chongqing PSK-Health Sci-tech Development Co., Ltd. ("PSK"), based in Chongqing, China and with over 200 employees around the country, has been dedicated to the research, development and manufacturing of ECP (External Counterpulsation) systems for more than 10 years. The research and development team of PSK is considered one of the strongest in the ECP field. The company has supported independent research and cooperation with universities in China for the future of ECP technology. PSK products are produced in compliance with ISO9001 and ISO13485 quality standards and have received CFDA and US FDA clearance as well as CE certification.
...forward lookin statement
gut ist:
Vaso kümmert sich um das eecp segment, von dessen Abkehr bisher im Rahmen der Diversifikation die Rede war. Zumindest bis sich gesetzliche (Krankenversicherer) Änderungen einstellen.
Vaso macht gemeinsame Sachen/einigt sich mit einem fiesen Konkurrenten den ich auch bei meinen Recherchen als mögliche Bedrohung aus dem chinesischen Raum eingestuft habe.
Das komplette Segment ist nicht ausgegliedert! So wie ich es verstehe, geht es hier darum den Plagiateur die Originale verkaufen zu lassen, um wenigstens einen Teil vom Kuchen abzubekommen. Evtl gibt es auch in China eine Nachfrage nach dem höherpreisigen, dafür mit medizinischen Studien hinterlegten Segment. China ist ein großer Markt.
Ich kann mir vorstellen, dass sich hier der erste Schritt zu einer tieferen Zusammenarbeit, vll auch Fusion zeigt.
Immerhin scheint auch PSK-China, Vaso nicht ignorieren zu können.
Schlecht ist:
Wir werden die "Erfolge" erst beim übernächsten Quartalsbericht sehen.
Der Kurs hat bisher nicht reagiert.
Sie haben sich den Raum geteilt. sollten PSK Produkte in Amerika verkauft werden, partizipiert Vaso und vice versa.
Ich sehe das positiv.
Dr. Kai Ruffmann is a cardiologist based in Germany who has been recommending and administering EECP® Therapy treatments for his patients for more than ten years. He has treated more than 250 patients in the hospital he worked at in the Black Forest region, and recently opened his own cardiology and internal medicine clinic in Baden-Baden.
Though various sites in Germany have provided EECP Therapy for many years, Dr. Ruffmann is the first German provider to get one of the German health insurance companies – a sickness fund – to provide reimbursement coverage for EECP Therapy, which is a huge win.
Germany has a universal multi-payer healthcare system with two main types of health insurance: “Law-enforced health insurance” (Gesetzliche Krankenversicherung), also known as sickness funds, and “Private” (Private Krankenversicherung). The “law enforced health insurance” is available for people who fall below a certain income level, and is provided through private non-profit sickness funds at common rates for all members. This insurance is paid for with joint employer-employee contributions.
The recently updated 2013 European Society of Cardiology Guidelines granted a IIa Level of Recommendation for EECP Therapy in treating refractory angina patients and this upgrade in status helps with reimbursement from insurance companies. At Vasomedical, we know that EECP Therapy changes lives, and we are very pleased to see that additional insurance companies around the world are beginning to accept this treatment and reimburse for it.
We appreciate Dr. Ruffmann’s commitment to his patients and his support of EECP Therapy on their behalf. We will continue to work with him to expand reimbursement coverage for more patients in Germany and Europe.
"We are excited to report that during the quarter, the Company generated positive cash flow of $4.2 million from operating activities, mainly due to our VasoHealthcare subsidiary achieving the highest commission rate, which is applied retroactively for all orders booked in 2013," stated Jun Ma, President and CEO of Vasomedical. "
.....
As our GEHC business continues to grow, we are taking advantage of the higher cash inflows and reinvesting in our business, while continuing our search for opportunities to complement and diversify our business."
"While total revenues slightly declined by 3% to $7.1 million for the quarter, mainly due to a decrease in EECP equipment sales, we are optimistic that our international performance will improve once the recently announced cooperative agreement with PSK-Health Sci-Tech Development Co. Ltd., the leading manufacturer of ECP therapy systems in China, is implemented.
This venture should help Vasomedical expand existing sales presence and tap into new geographical territories internationally, as well as substantially reduce sales and marketing costs. We are currently in the process of reorganizing our EECP business model, both domestically and internationally, in view of this cooperative agreement."
"In addition, we strengthened our product portfolio within BIOX with the introduction of MobiCare™ system, a patented wireless multi-parameter patient monitoring system, and expect our China operations to grow. Looking forward, we believe we are well positioned to achieve profitability and maintain positive cash flow, and continue to achieve superior performance from our sales representation business," concluded Dr. Ma.
Three Months Ended March 31, 2014 Financial Results
For the three months ended March 31, 2014, revenue decreased by 3% to $7.1 million from $7.3 million for the same period of 2013. This is mainly attributable to a 45% decline in equipment sales due to decreased EECP® revenues, which was partially offset by the 4% growth in commission revenues to $6.2 million, from our Sales Representation segment. As we have stated previously, EECP sales are expected to remain soft unless acceptance level for its currently indicated use and reimbursement policies change positively. The uncertain timing for this to occur was ultimately the reason behind the Company's diversification strategy, which included entering the GEHC representation agreement and acquiring its Chinese operating companies.
Gross profit for the first quarter of 2014 increased 2% to $5.2 million, compared with $5.1 million for the first quarter of 2013. This increase is primarily a result of the higher commission revenues from the Sales Representation segment, arising from higher commission rates for orders booked in 2013, partially offset by lower equipment shipments in the Equipment Segment.
Selling, general and administrative (SG&A) expenses for the first quarter of 2014 was $6.0 million or 85% of revenues, compared with $5.6 million, or 77% of revenues for the same period last year. This is mainly attributable to the annual sales team meeting in the Sales Representation segment during the quarter, which took place in the second quarter last year.
Net loss for the three months ended March 31, 2014 was $1.0 million, a 60% increased loss compared with a net loss of $652,000 for the three months ended March 31, 2013, as a result of an 8% increase in selling, general and administrative costs.
Net cash increased by $4.0 million to $12.0 million at March 31, 2014, compared with net cash of $8.0 million as of December 31, 2013. This increase in cash is mainly attributable to the significantly higher commission rate generated in the fourth quarter of 2013, resulting in significant cash inflows early in 2014. Based on current forecast, we anticipate cash flow from operating activities to be positive for 2014.
Deferred revenue remains substantial, at approximately $17.0 million as of March 31, 2014, to be recognized in the future when the underlying equipment is delivered and accepted at the customer site.
Conference Call Information
The Company will host a conference call today at 10:00 a.m. ET featuring remarks by Jun Ma, Ph.D., President and CEO of Vasomedical, and Michael Beecher, Chief Financial Officer of Vasomedical. To dial into the conference call, please dial 1-866-393-1344 from the U.S. or 1-631-291-4669, internationally. All dial-in participants must use the following code to access the call: 42076306. Please call at least five minutes before the scheduled start time. The conference call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedical's website, www.vasomedical.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
A replay of the conference call will be available approximately two hours after completion of the live conference call at www.vasomedical.com. To access the dial-in replay of the call, which will be available until June 14, 2014, please dial 1-855-859-2056 or 1-404-537-3406. All dial-in participants must use the following code to access the call: 42076306.
ist für die meisten stocks business as usual, aber bei vaso könnte da mehr hinter stecken.
ich bin gespannt.
geld, gedanken, geduld und glück...
eindeutig unbeachtet und hart unterbewertet das moped.
einlesen und position beziehen.
In Thailand last week, engineers from Biox Instruments Co. Ltd., a subsidiary of Vasomedical, conducted the first demonstration of our MobiCare™ patient monitoring system"s capabilities in a live surgical procedure at Bangpakok 8 International Hospital under the supervision of Dr. Jantra Tipchai.
Not much reaction with stock price. If any it was negative. Any thoughts on weather this is good or bad for the company? I guess sell the news may explain the negative stock price action.
...Products in Brazil.
http://finance.yahoo.com/news/...ovals-market-products-130000401.html
management n bischen mau. produkt, meiner ansicht nach sehr gut, wer in deu handeln kann, los gehts
Zahlen sind raus. mal schauen wo die Reise hingeht.
http://finance.yahoo.com/news/...ancial-results-fourth-130000442.html
http://data.cnbc.com/quotes/VASO 435k bisher heute. das riecht nach Ausbruch.
Quartalsbericht über cnbc zugänglich.
Vasomedical Announces First Quarter 2015 Financial Results
The Company Reports 5% Revenue Growth Year-Over-Year
Marketwired
Vasomedical, Inc. 4 hours ago
WESTBURY, NY--(Marketwired - May 14, 2015) - Vasomedical, Inc. ("Vasomedical") (OTCBB: VASO) today reported its operating results for the three months ended March 31, 2015.
"We are excited to report that during the quarter, the Company generated a 5% increase in revenue compared to the first quarter of 2014 as well as a positive cash flow of $6.3 million from operating activities, thanks to improved performance in the Equipment segment and in the Sales Representation segment," commented Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc. "While we usually incur a loss for the beginning part of the fiscal year due to the seasonality of our business, our net loss for the first quarter of 2015 reduced significantly to $252 thousand compared to a loss of $1.0 million for the same quarter a year ago. Given this momentum, we expect to maintain annual profitability in 2015."
"Our recently formed IT segment, which only began operations in the second half of 2014, accounted for an operating loss of $355 thousand for the quarter, but through its booked orders and pipeline, it is beginning to penetrate the market and starting to show the potential for significant future revenue growth. We are optimistic about the future of this business as well as our VSK joint venture for international EECP sales, which began operations in the first quarter of 2015, and we anticipate positive results from these new endeavors in the near future," concluded Dr. Ma.
Three Months Ended March 31, 2015 Financial Results
For the three months ended March 31, 2015, revenue increased by 5% to $7.5 million from $7.1 million for the same period of 2014. This is mainly attributable to an increase of 25% in our Equipment segment revenue resulting from an increase in volume of EECP system sales and an increase in sales in our China operations. Commission revenue in our Sales Representation segment increased by 2% as a result of an increase in equipment deliveries by GEHC.
Gross profit for the first quarter of 2015 increased 8% to $5.6 million, compared with $5.2 million for the first quarter of 2014. Gross profit increased due to an increase in margin in our Equipment segment as a result of an increase in EECP system shipments, and an increase in profit margin in our Sales Representation segment due to an increase in deliveries of equipment and a decrease in commission expense.
Selling, general and administrative (SG&A) expenses for the first quarter of 2015 decreased 5% to $5.7 million or 77% of revenues, compared with $6.0 million, or 85% of revenues for the same period last year. This is mainly attributable to our cost reduction program in our Equipment segment and the holding of the annual national sales meeting in the Sales Representation segment in the second quarter of 2015 instead of the first quarter as in 2014.
Net loss for the three months ended March 31, 2015 was $0.3 million, a 76% decrease compared with a net loss of $1.0 million for the three months ended March 31, 2014. Included in the loss was the approximately $0.4 million loss in our newly launched IT segment. The significant loss reduction was a result of an increase in gross profit and reduced SG&A expenses as discussed above.
As of March 31, 2015, the Company had cash and cash equivalents of approximately $15.3 million and short-term investments of $109 thousand. We anticipate continued positive cash flows from operations for the current year.
Conference Call Information
The Company will host a conference call at a date to be announced later.
About Vasomedical
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through four wholly owned subsidiaries: Vasomedical Solutions, Inc., Vasomedical Global Corp., Vaso Diagnostics, Inc. d.b.a. VasoHealthcare, and VasoHealthcare IT Corp. Vasomedical Solutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems and other medical equipment operations; Vasomedical Global operates the Company's China-based subsidiaries; VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments; and VasoHealthcare IT is a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support. Additional information is available on the Company's website at www.vasomedical.com.
werde mich also hier nicht mit währungsgewinnen begnuegen.
http://commcgi.cc.stonybrook.edu/am2/publish/...Research_Center.shtml
wann kommen hier ergebnisse?
http://www.newindianexpress.com/cities/chennai/.../article2828085.ece
das ding kommt bestimmt nochmal hoch. immerhin bleiben sie profitabel.
Vasomedical Acquires Network Service Company NetWolves
http://finance.yahoo.com/news/...ork-company-netwolves-130000315.html
WESTBURY, NY / ACCESSWIRE / June 1, 2015 / Vasomedical, Inc. ("Vasomedical") (VASO) today announced the acquisition of all assets of NetWolves, LLC and affiliates (collectively "NetWolves") on May 29, 2015.
"The NetWolves acquisition is extremely important to the future success of Vasomedical, both strategically and operationally, as it immediately eliminates our prior need to build a comprehensive technology infrastructure for our recently launched healthcare IT business. At the same time, it further expands our business into network services especially for the customers in healthcare provision, where reliable, high-fidelity and secure network connectivity is in high demand," stated Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc. "More significantly, it also provides us with the platform for huge potential growth in the rapidly expanding telemedicine and connected healthcare markets."
"NetWolves, as a stand-alone private entity, has been a growing and profitable business for over six years. As it will be integrated into our healthcare IT business to provide implementation, training and support services to our healthcare IT value-added-resale operation, its technical expertise in IT infrastructure and network connectivity readily complements our market presence and customer relations in the healthcare industry. It also presents us with significant cross-selling and up-selling opportunities for its proprietary managed network services to our existing entrenched nationwide customer base in the diagnostic imaging business. We are very excited by the acquisition and are even more optimistic about the future of our new healthcare IT segment now that we have established a solid technical and customer foundation," concluded Dr. Ma.
NetWolves, LLC, a Florida based limited liability company, and its affiliates have been engaged in managed network services with an extensive, proprietary service platform to a broad base of customers - predominantly domestically based, however supporting their needs globally as well - including many Fortune 500 corporations. Substantially all of its customers are under multi-year agreements which provide us with a recurring revenue model to complement our existing operations. Fiscal 2013 and 2014 revenues were approximately $28 million and $30 million, respectively, and adjusted operating income was approximately $1.2 million and $1.4 million, respectively. Vasomedical completed the acquisition of all NetWolves assets on May 29, 2015, including all proprietary technology and intellectual properties, service provider and customer contracts, licenses, etc., for $18 million in cash and the assumption of certain liabilities, virtually all of which are operations related.
"We are very excited to be part of the Vasomedical team," commented Peter Castle, President and Chief Executive Officer of NetWolves, who is also a director of Vasomedical. "We believe the combined operations are a perfect fit and come at an opportune time for us to potentially be a major participant in the rapidly growing healthcare connectivity market. A number of financial institutions have already expressed interest in assisting us in the rapid expansion of business."
Conference Call Information
The Company will host a conference call on June 10, 2015 at 10:00 a.m. ET to discuss first quarter 2015 financial results as well as the acquisition and integration of NetWolves, featuring remarks by Jun Ma, Ph.D., President and CEO of Vasomedical, Michael Beecher, Chief Financial Officer of Vasomedical and Peter Castle, President of NetWolves, who will continue to manage our new NetWolves subsidiary. To dial into the conference call, please dial 1-877-407-8033 from the U.S. or 1-201-689-8033, internationally. Please call at least five minutes before the scheduled start time. The conference call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedical's website, www.vasomedical.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.
Bei Vaso:
Peter C. Castle, Chairman of the Audit Committee
Peter Castle has been a director since August 2010. Mr. Castle is currently the President and Chief Operating
Officer of NetWolves Corporation, where he has been employed since 1998. Mr. Castle also held the position of Chief
Financial Officer from 2001 until October 2009, Vice President of Finance since January 2000, Controller from August
1998 until December 1999 and Treasurer and Secretary from August 1999. NetWolves is a global telecommunications
and Internet managed services provider offering single-source network solutions that provides multi-carrier and multivendor
implementation to over 1,000 customers worldwide.
Bei Net Wolves:
Peter Castle, President/Chief Executive Officer
Mr. Castle joined NetWolves in August 1998 as Controller, and was named Chief Financial Officer in January 2000. He was instrumental in that capacity, navigating Wall Street, raising equity and debt capital. In addition to his responsibilities as CFO, Mr. Castle served as Chief Restructuring Officer in 2007 and 2008, leading the transition from a public to a private company. Mr. Castle was named Chief Operating Officer of NetWolves in September 2009. In April 2010, Mr. Castle was named President of NetWolves by the Board of Directors, and is responsible for setting and implementing the strategic direction of the company. In November 2013, Mr. Castle was unanimously elected Chief Executive Officer by the Board of the Directors. Though he continues to manage the daily Operations of the company from the corporate office in Tampa, FL, Mr. Castle’s main focus is the development and strategic growth of the company. Prior to NetWolves, Mr. Castle was responsible for the Southeast Regional Finance or Magellan Health Service, Inc. a $1.6 billion managed health care company. Mr. Castle served in the US Army in the capacity of Non Commissioned Officer and then Commissioned Officer, leaving with the rank of 1st Lieutenant, holding various leadership positions and serving in both domestic and foreign posts. He received numerous certificates, awards and commendations, including a three time recipient of the Army Commendation Medal.